CANFCan-Fite BioPharma Ltd.

NYSE canfite.com


$ 2.74 $ 0.02 (0.55 %)    

Friday, 21-Jun-2024 15:57:59 EDT
QQQ $ 480.84 $ -1.29 (-0.27 %)
DIA $ 391.56 $ -0.73 (-0.19 %)
SPY $ 544.47 $ -0.73 (-0.13 %)
TLT $ 93.96 $ 0.00 (0 %)
GLD $ 214.79 $ -3.38 (-1.55 %)
$ 2.725
$ 2.71
$ 0.00 x 0
$ 0.00 x 0
$ 2.70 - $ 2.74
$ 1.81 - $ 4.48
39,842
na
3.71B
$ 0.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 can-fite-biopharma-says-its-phase-3-study-for-namodenoson-for-advanced-liver-cancer-is-31-recruiting-medical-centers-namodenoson-has-orphan-drug-status-from-fda-and-european-medicines-agency-and-fda-fast-track-status

A compassionate use program has also been ongoing in Israel and Romania. 

 hc-wainwright--co-reiterates-buy-on-can-fite-biofarma-maintains-18-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $18 pric...

 can-fite-received-notice-of-allowance-from-the-european-patent-office-for-the-treatment-of-erectile-dysfunction-with-cf602

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

 can-fite-biopharma-announced-it-published-an-article-in-the-experimental-and-therapeutic-medicine-journal-long-term-complete-response-to-namodenoson-in-liver-cancer-with-child-pugh-b-cirrhosis

The Patient Participated In The Phase Ii Liver Cancer Study And Has Been Treated With Namodenoson For >7 Years Under Compass...

 can-fites-namodenoson-featured-in-biomedicines-for-liver-cancer-and-mash-treatment-insights

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

 can-fite-biopharma-submits-fda-with-an-ind-application-to-conduct-phase-iib-clinical-trial-of-namodenoson-in-mash-patients

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

 can-fite-biofarma-fy-gaap-eps-001-same-yoy-sales-74300k-down-from-81000k-yoy

Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year....

 can-fite-expands-the-out-licensing-deal-with-ewopharma-to-include-the-pancreatic-cancer-indication

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

 can-fites-latest-innovation-namodenoson-shows-significant-results-in-obesity-reduction

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

 can-fite-receives-positive-response-from-fda-on-pediatric-study-plan-for-treatment-of-children-suffering-from-psoriasis-with-piclidenoson

The plan has been submitted to allow enrollment of children with psoriasis to Can-Fite's upcoming Phase 3 pivotal clinical ...

 can-fite-biofarma-9m-sales-58800k-down-from-61300k-yoy

Can Fite Biofarma (AMEX:CANF) reported $588.00 thousand in sales this quarter. This is a 4.08 percent decrease over sales of $6...